Oxford BioDynamics (GB:OBD) has released an update.
Oxford BioDynamics, a pioneer in precision clinical diagnostics, was recently in the news for its involvement in the UK Cancer Immunotherapy Response Research Platform (CIRRP) funding bid. Although the company’s EpiSwitch consortium was not awarded the funding, OBD remains committed to the advancement of its Checkpoint Inhibitor Response Test (CiRT) and continues to innovate in the field of genomics-based diagnostics. The company boasts a growing portfolio of tests, including their highly accurate CiRT, aimed at improving personalized healthcare.
For further insights into GB:OBD stock, check out TipRanks’ Stock Analysis page.
